A new dawn for Oxford BioMedica…again
This article was originally published in Scrip
For Oxford BioMedica 2013 was quite an annus horribilis. However, the UK biotechnology firm is still confident it will rise up from the ashes this year – with CEO John Dawson saying that despite reporting pre-tax losses of more than £12m last year, the company is "operationally now in its strongest position ever."
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.